AKTS

Aktis Oncology Inc

May 15 • 04:00PM ET

19.55

+0.05 0.26 %

Healthcare • Biotechnology • USA • Small • NASD

| Held by: VTI IWM VXF VTWO SCHA IWO IWN ITOT SCHB IWV

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	45.20%	Shs Outstand	55.28M	Perf Week	5.11%
Market Cap	1.04B	Forward P/E	-	EPS next Y	-2.31	Insider Trans	35.71%	Shs Float	28.47M	Perf Month	5.11%
Enterprise Value	517.07M	PEG	-	EPS next Q	-0.44	Inst Own	17.21%	Short Float	9.03%	Perf Quarter	10.08%
Income	-	P/S	-	EPS this Y	97.91%	Inst Trans	19.36%	Short Ratio	7.81	Perf Half Y	-
Sales	-	P/B	2.14	EPS next Y	-40.73%	ROA	-	Short Interest	2.57M	Perf YTD	-12.72%
Book/sh	9.16	P/C	1.94	EPS next 5Y	64.23%	ROE	-	52W High	29.16 -32.96%	Perf Year	-
Cash/sh	10.08	P/FCF	-	EPS past 3/5Y	-47.94% -	ROIC	-	52W Low	14.72 32.81%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.82% 7.27%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.49	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	52.40	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.49	EPS Q/Q	-	SMA20	-0.95%	Beta	-	Target Price	32.50
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	4.53%	Rel Volume	0.43	Prev Close	19.50
Employees	79	LT Debt/Eq	0.02	Earnings	May 11 AMC	SMA200	1.60%	Avg Volume	329.25K	Price	19.55
IPO	Jan 09, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-0.81% 44.71%	Trades		Volume	142,837	Change	0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-26	Initiated	William Blair	Outperform
Mar-09-26	Initiated	H.C. Wainwright	Buy	$30
Feb-03-26	Initiated	TD Cowen	Buy
Feb-03-26	Initiated	Leerink Partners	Outperform	$31
Feb-03-26	Initiated	JP Morgan	Overweight	$30
Feb-03-26	Initiated	BofA Securities	Buy	$34

May-11-26 04:56PM	Aktis: Q1 Earnings Snapshot (Associated Press) +7.99%
04:01PM	Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026 (GlobeNewswire)
May-06-26 08:00AM	Aktis Oncology to Present at the BofA Securities Health Care Conference (GlobeNewswire)
May-04-26 04:05PM	Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (GlobeNewswire)
Apr-21-26 05:00PM	Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +7.32%
08:00AM	Loading…
Apr-16-26 08:00AM	Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors (GlobeNewswire)
Mar-30-26 04:01PM	Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results (GlobeNewswire) +8.89% +8.16%
Mar-03-26 08:02PM	Aktis Oncology Details Radiopharma Expansion, Fast Track Win for AKY-1189 at TD Cowen Conference (MarketBeat)
Feb-24-26 04:05PM	Aktis Oncology to Present at Upcoming March Investor Conferences (GlobeNewswire)
12:02PM	Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO (Bloomberg)
08:00AM	Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate (GlobeNewswire)
Feb-05-26 01:21PM	Merck veteran Perlmutter-led Eikon Therapeutics valued at $860 million in Nasdaq debut (Reuters)
Feb-03-26 09:34AM	Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Jan-27-26 11:39AM	Should You Buy PICS Stock After the PicPay IPO? (Barchart)
Jan-19-26 08:45AM	Huge Insider Buying Now at This Insurance Giant and 2 Biotechs (24/7 Wall St.)
07:00AM	Loading…
Jan-17-26 07:00AM	MarketBeat Week in Review 01/12 - 01/16 (MarketBeat)
Jan-14-26 09:31AM	A Fresh IPO That Long-Term Investors Shouldn't Ignore (MarketBeat)
Jan-13-26 06:30AM	Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-09-26 12:58PM	Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets (Business Wire)

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Co-Founder & ChairmanMr. Todd Foley M.B.A.

PresidentDr. Matthew Roden Ph.D.

Chief Scientific OfficerDr. Paul L. Feldman Ph.D.

Ph.D.Dr. Akos Czibere M.D.

Co-Founder & Member of Scientific Advisory BoardDr. Patrick A. Baeuerle Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foley Todd	Director	Jan 12 '26	Buy	18.00	232,870	4,191,660	4,235,403	Jan 14 06:20 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Jan 12 '26	Buy	18.00	1,112,777	20,029,986	10,260,064	Jan 14 06:19 PM
GADICKE ANSBERT	10% Owner	Jan 12 '26	Buy	18.00	1,112,777	20,029,986	10,260,064	Jan 14 06:17 PM
EcoR1 Capital, LLC	Director	Jan 12 '26	Buy	18.00	2,222,222	39,999,996	4,348,658	Jan 12 08:28 PM
Vida Ventures II, LLC	10% Owner	Jan 12 '26	Buy	18.00	835,000	15,030,000	5,671,825	Jan 12 05:10 PM
Kim Helen Susan	Director	Jan 12 '26	Buy	18.00	835,000	15,030,000	5,671,825	Jan 12 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTS

Aktis Oncology Inc

Upgrade your Finviz experience